Bioxcel Therapeutics, Inc.NASDAQ: BTAI

BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder

· Issued by Bioxcel Therapeutics, Inc.
Watch Bioxcel Therapeutics explain itBioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call · Replay · Nov 14, 2024

Highly statistically significant improvements in PEC score observed vs. placebo (p

Company analysis